Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis
Disease Markers · 01.11.2023 · 2023 · 1-8
DOI: 10.1155/2023/9013756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 01.11.2023. Verfasst von Shoko Miyamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hyogo Medical University, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Dupilumab (DUP) is the first biological agent used treating atopic dermatitis (AD). Notwithstanding its high cost, the type of patient group for which the drug is effective remains unclear. In this retrospective study, we aimed to identify novel and reliable biomarkers which can be measured before DUP administration and to predict the efficacy of DUP. Serum samples from 19 patients with AD treated with DUP were analysed by metabolome analysis using gas chromatography–mass spectrometry. Total 148 metabolites were detected, and the relative values of the metabolites were compared between the patient group that achieved 75% improvement in Eczema Area and Severity Index 16 weeks after administration of DUP (high responders: HR; n = 11) and that did not (low responders: LR; n = 8). The HR and LR groups had significant differences in the relative values of the eight metabolites (lactic acid, alanine, glyceric acid, fumaric acid, nonanoic acid, ribose, sorbitol, and ornithine), with ribose emerging as the best. Furthermore, we evaluated the serum concentrations of ribose and found that ribose may be a useful metabolite biomarker for predicting the efficacy of DUP in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hyogo Medical University, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
- Department of Dermatology Institute of Biomedical Sciences, Tokushima University Graduate School, 2-50-1, Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
- Imai Adult and Pediatric Dermatology Clinic, 5-1-1, Ebie, Fukushima-ku, Osaka, Osaka 553-0001, Japan.
- Department of Dermatology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie 514-8507, Japan.
- Department of Omics Medicine, Hyogo Medical University, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
- Department of Biosphere Sciences, School of Human Sciences, Kobe College, 4-1, Okadayama, Nishinomiya, Hyogo 662-8505, Japan.
ORCID-Profile: Shoko Miyamoto, Yasutomo Imai, Shin Nishiumi
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Miyamoto, S., Imai, Y., Matsutani, M., Nagai, M., Yamanishi, K., Kanazawa, N., & Nishiumi, S. (2023). Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis. Disease Markers, 2023, 1-8. https://doi.org/10.1155/2023/9013756
Vancouver
Miyamoto S, Imai Y, Matsutani M, Nagai M, Yamanishi K, Kanazawa N, et al. Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis. Disease Markers. 2023;2023:1-8. doi:10.1155/2023/9013756
BibTeX
@article{Miyamoto2023,
author = {Miyamoto, Shoko and Imai, Yasutomo and Matsutani, Masako and Nagai, Makoto and Yamanishi, Kiyofumi and Kanazawa, Nobuo and Nishiumi, Shin},
title = {Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis},
journal = {Disease Markers},
year = {2023},
volume = {2023},
pages = {1--8},
doi = {10.1155/2023/9013756}
}
EUVIMED